AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is focused on developing gene therapies for rare diseases and is currently conducting human clinical trials using AAV-based technologies.

AGTC's advanced programs aim to treat conditions like X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts of the presentation via the company's website.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23^rd Annual Global Investment Conference on September 13^th, 2021.

Audio webcasts of the presentation can be accessed by visiting http://ir.agtc.com/eventsand-presentations. A replay will be available on the Company's website following the events.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR CONTACT:

Jonathan Nugent
Stern IR
T: 212-698-8698
Jonathan.nugent@sternir.com

Corporate Contacts:

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When is AGTC presenting at the H.C. Wainwright Conference?

AGTC will present on September 13, 2021.

What is AGTC's focus in biotechnology?

AGTC develops gene therapies for rare diseases, particularly in ophthalmology, otology, and CNS disorders.

Where can I find the presentation audio for AGTC's conference?

The audio webcasts can be accessed at AGTC's website under events and presentations.

What are AGTC's clinical programs targeting?

AGTC's clinical programs target X-linked retinitis pigmentosa and achromatopsia.

What technology does AGTC utilize for its therapies?

AGTC utilizes adeno-associated virus (AAV)-based technologies for its gene therapies.